Summit Global Investments Sells 15,559 Shares of Merck & Co., Inc. $MRK

Key Points

• Summit Global Investments cut its Merck stake by 23% in the second quarter, selling 15,559 shares and retaining 52,039 shares valued at approximately $6.7 million. Institutional investors collectively own 76.07% of Merck.
• Merck and Moderna reported positive Phase 3 results for their personalized mRNA melanoma vaccine used with Keytruda, potentially strengthening Merck’s oncology pipeline ahead of Keytruda’s expected loss of exclusivity.
• Merck’s shares opened at $149.25, near their 52-week high, while analysts issued mixed signals: several raised price targets, but RBC and Jefferies cited valuation concerns and competitive risks. Insiders have sold roughly $30 million of stock over the past 90 days.

Summit Global Investments decreased its stake in shares of Merck & Co., Inc. (NYSE:MRK - Free Report) by 23.0% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 52,039 shares of the company's stock after selling 15,559 shares during the period. Summit Global Investments' holdings in Merck & Co., Inc. were worth $6,687,000 at the end of the most recent quarter.

Several other institutional investors have also bought and sold shares of the stock. Brighton Jones LLC boosted its holdings in Merck & Co., Inc. by 29.5% during the 4th quarter. Brighton Jones LLC now owns 38,278 shares of the company's stock worth $3,808,000 after acquiring an additional 8,710 shares during the last quarter. Sivia Capital Partners LLC raised its holdings in shares of Merck & Co., Inc. by 52.2% in the second quarter. Sivia Capital Partners LLC now owns 11,494 shares of the company's stock valued at $910,000 after purchasing an additional 3,941 shares during the last quarter. Diversify Advisory Services LLC lifted its position in shares of Merck & Co., Inc. by 94.1% during the second quarter. Diversify Advisory Services LLC now owns 32,256 shares of the company's stock valued at $2,590,000 after purchasing an additional 15,636 shares in the last quarter. Diversify Wealth Management LLC boosted its holdings in Merck & Co., Inc. by 22.2% during the second quarter. Diversify Wealth Management LLC now owns 38,031 shares of the company's stock worth $3,054,000 after purchasing an additional 6,897 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in Merck & Co., Inc. by 111.7% during the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 681,128 shares of the company's stock worth $53,918,000 after purchasing an additional 359,356 shares during the last quarter. Institutional investors own 76.07% of the company's stock.

Insider Buying and Selling at Merck & Co., Inc.

In other news, EVP David Michael Williams sold 52,847 shares of Merck & Co., Inc. stock in a transaction dated Wednesday, August 5th. The shares were sold at an average price of $128.77, for a total value of $6,805,108.19. Following the completion of the transaction, the executive vice president owned 31,716 shares in the company, valued at $4,084,069.32. This trade represents a 62.49% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Chirfi Guindo sold 10,000 shares of the business's stock in a transaction that occurred on Thursday, August 13th. The shares were sold at an average price of $135.00, for a total transaction of $1,350,000.00. Following the completion of the sale, the executive vice president directly owned 36,613 shares in the company, valued at approximately $4,942,755. This trade represents a 21.45% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders sold 228,238 shares of company stock valued at $29,977,783. Insiders own 0.17% of the company's stock.

Merck & Co., Inc. News Roundup

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck and Moderna reported that their individualized mRNA vaccine, used with Merck’s Keytruda, met the Phase 3 primary endpoint in high-risk melanoma. The combination improved recurrence-free survival and distant-metastasis-free survival compared with Keytruda alone, marking the first positive late-stage result for an mRNA cancer vaccine. The result could expand Merck’s oncology pipeline and help address the eventual loss of Keytruda exclusivity. Merck, Moderna say melanoma skin cancer vaccine meets goals in large trial
• Positive Sentiment: Morgan Stanley upgraded MRK to overweight and raised its price target to $179 from $116, while UBS lifted its target to $175 and BMO raised its target to $170, reflecting increased confidence in the cancer-vaccine opportunity and Merck’s broader growth prospects. Merck upgraded at Morgan Stanley after cancer trial win; RBC downgrades
• Neutral Sentiment: Analysts cautioned that the initial results are not a complete regulatory or commercial victory. Full data, regulatory approval expected no earlier than 2027, manufacturing execution and the therapy’s eventual pricing and market adoption remain key uncertainties. Moderna's Cancer Vaccine: Are Investors Putting The Cart Before The Horse?
• Negative Sentiment: RBC downgraded MRK to sector perform and set a $150 target, arguing that the roughly $150 valuation is unusually demanding for a company facing a major Keytruda loss of exclusivity in about two years. Jefferies also moved the stock to hold, creating a valuation overhang despite the trial success. Merck’s Cancer-Vaccine Trial Results Surpassed Expectations – So, Why Did RBC Downgrade MRK Stock?
• Negative Sentiment: Broader healthcare weakness and profit-taking after Merck’s sharp rally are adding pressure, while the stock’s elevated valuation leaves less room for disappointment. Sector Update: Healthcare Stocks Fall Thursday Afternoon

Merck & Co., Inc. Stock Performance

NYSE:MRK opened at $149.25 on Friday. The company has a debt-to-equity ratio of 1.22, a current ratio of 1.32 and a quick ratio of 1.10. The business has a fifty day simple moving average of $127.43 and a two-hundred day simple moving average of $121.01. Merck & Co., Inc. has a 1 year low of $77.58 and a 1 year high of $153.50. The company has a market capitalization of $368.23 billion, a P/E ratio of 119.40, a P/E/G ratio of 6.56 and a beta of 0.19.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last issued its quarterly earnings results on Tuesday, August 4th. The company reported ($0.13) EPS for the quarter, beating analysts' consensus estimates of ($0.26) by $0.13. The firm had revenue of $16.61 billion for the quarter, compared to analysts' expectations of $16.37 billion. Merck & Co., Inc. had a return on equity of 16.73% and a net margin of 4.77%.The business's revenue for the quarter was up 5.1% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $2.13 EPS. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. On average, analysts expect that Merck & Co., Inc. will post 2.77 earnings per share for the current year.

Merck & Co., Inc. Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 7th. Shareholders of record on Tuesday, September 15th will be issued a dividend of $0.85 per share. The ex-dividend date of this dividend is Tuesday, September 15th. This represents a $3.40 annualized dividend and a yield of 2.3%. Merck & Co., Inc.'s dividend payout ratio is 272.00%.

Analysts Set New Price Targets

Several research firms have commented on MRK. JPMorgan Chase & Co. lifted their target price on shares of Merck & Co., Inc. from $135.00 to $140.00 and gave the stock an "overweight" rating in a research report on Monday, July 13th. Morgan Stanley raised Merck & Co., Inc. from an "equal weight" rating to an "overweight" rating and increased their price target for the company from $116.00 to $179.00 in a research report on Thursday. UBS Group lifted their price target on Merck & Co., Inc. from $145.00 to $175.00 and gave the stock a "buy" rating in a report on Thursday. Guggenheim boosted their price objective on Merck & Co., Inc. from $145.00 to $146.00 and gave the stock a "buy" rating in a research report on Wednesday, August 5th. Finally, BMO Capital Markets upped their price objective on Merck & Co., Inc. from $142.00 to $170.00 and gave the company an "outperform" rating in a research note on Thursday. Fifteen investment analysts have rated the stock with a Buy rating and eight have given a Hold rating to the company. According to data from MarketBeat.com, Merck & Co., Inc. has an average rating of "Moderate Buy" and an average price target of $142.10.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source